Safety with GLP-1: No known interactions between glutathione (any form), NAC, and semaglutide or tirzepatide
They compared rates of clinically recorded alopecia in adults with type 2 diabetes who started GLP-1 receptor agonists against those starting SGLT-2 inhibitors or DPP-4 inhibitors, two other standard diabetes drug classes
As the FDA has cautioned, unapproved compounded semaglutide drugs do not have the same safety, quality, and effectiveness assurances as Novo Nordisks FDA-approved semaglutide medicines, and patients should not use a compounded drug if an approved drug is available. Theres huge safety implications, Ryder says
[24] Gallwitz B, Giorgino F
Patients consistently see progress when they follow a program that balances science with ongoing care